GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » European Medical Solutions (LTS:0RGO) » Definitions » Debt-to-EBITDA

European Medical Solutions (LTS:0RGO) Debt-to-EBITDA : 5.08 (As of Jun. 2024)


View and export this data going back to 2016. Start your Free Trial

What is European Medical Solutions Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

European Medical Solutions's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €6.18 Mil. European Medical Solutions's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €11.70 Mil. European Medical Solutions's annualized EBITDA for the quarter that ended in Jun. 2024 was €3.52 Mil. European Medical Solutions's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 5.08.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for European Medical Solutions's Debt-to-EBITDA or its related term are showing as below:

LTS:0RGO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -12.24   Med: -0.12   Max: 10.37
Current: 10.37

During the past 12 years, the highest Debt-to-EBITDA Ratio of European Medical Solutions was 10.37. The lowest was -12.24. And the median was -0.12.

LTS:0RGO's Debt-to-EBITDA is ranked worse than
87.87% of 272 companies
in the Biotechnology industry
Industry Median: 1.54 vs LTS:0RGO: 10.37

European Medical Solutions Debt-to-EBITDA Historical Data

The historical data trend for European Medical Solutions's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

European Medical Solutions Debt-to-EBITDA Chart

European Medical Solutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.32 -7.75 6.84 -12.24 9.46

European Medical Solutions Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.30 41.68 4.39 -258.45 5.08

Competitive Comparison of European Medical Solutions's Debt-to-EBITDA

For the Biotechnology subindustry, European Medical Solutions's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


European Medical Solutions's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, European Medical Solutions's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where European Medical Solutions's Debt-to-EBITDA falls into.



European Medical Solutions Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

European Medical Solutions's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.058 + 13.067) / 2.022
=9.46

European Medical Solutions's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(6.179 + 11.697) / 3.522
=5.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2024) EBITDA data.


European Medical Solutions  (LTS:0RGO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


European Medical Solutions Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of European Medical Solutions's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


European Medical Solutions Business Description

Traded in Other Exchanges
Address
7 Rue des Chasseurs Ardennais, Liege, BEL, 4031
European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.

European Medical Solutions Headlines

No Headlines